[MDCO] The Medicines Company

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 35.16 Change: 0.59 (1.71%)
Ext. hours: Change: 0 (0%)

chart MDCO

Refresh chart

Strongest Trends Summary For MDCO

MDCO is in the medium-term up 26% above S&P in 3 months and down -33% below S&P in 1 year. In the long-term down -45% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria, including Acinetobacter species; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent for the prevention of platelet activation and aggregation; Oritavancin, an investigational intravenous antibiotic for the treatment of acute bacterial skin related

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -31.16% Sales Growth - Q/Q-33.76% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-0.97% ROE-2.21% ROI-1.29%
Current Ratio2.51 Quick Ratio2.15 Long Term Debt/Equity1.06 Debt Ratio0.35
Gross Margin62.22% Operating Margin-13.51% Net Profit Margin-3.29% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities397.92 M Cash From Investing Activities-119.38 M Cash From Operating Activities-41.03 M Gross Profit53.47 M
Net Profit-46.59 M Operating Profit-78.99 M Total Assets2.29 B Total Current Assets881.74 M
Total Current Liabilities351.44 M Total Debt562.73 M Total Liabilities1.29 B Total Revenue90.47 M
Technical Data
High 52 week40.94 Low 52 week17.26 Last close25.01 Last change2.75%
RSI56.55 Average true range0.91 Beta0.97 Volume390.36 K
Simple moving average 20 days5.42% Simple moving average 50 days18.84% Simple moving average 200 days-15.39%
Performance Data
Performance Week0.97% Performance Month24.06% Performance Quart22.36% Performance Half-36.28%
Performance Year-16.16% Performance Year-to-date30.67% Volatility daily2.3% Volatility weekly5.15%
Volatility monthly10.55% Volatility yearly36.55% Relative Volume137.41% Average Volume1.3 M
New High New Low

News

2019-03-18 18:51:10 | Alnylam's ALNY Impressive Pipeline Drives Share Price

2019-03-15 16:24:16 | Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?

2019-03-12 10:18:02 | Implied Volatility Surging for Medicines Company MDCO Stock Options

2019-03-12 09:59:01 | Alnylam Files Application for Hypertension Candidate in UK

2019-03-10 19:14:42 | Insider Buys Of The Week: Arconic, CenturyLink, Hain Celestial and More

2019-03-08 16:32:33 | Could A Patent Battle Force Sanofi To Snap Up This Biotech Stock?

2019-03-08 14:51:34 | If You Had Bought Medicines NASDAQ:MDCO Stock A Year Ago, You’d Be Sitting On A 28% Loss, Today

2019-03-08 08:59:00 | Insider Buying Is Still Alive and Well at These 3 Companies

2019-03-08 02:08:55 | [$$] A disease in remission? New hope in the quest to cure HIV

2019-03-07 09:00:02 | Alnylam Stock Down Despite Positive Phase III Givosiran Data

2019-02-28 09:50:02 | Medicines Company MDCO Q4 Loss Widens, Inclisiran in Focus

2019-02-28 02:29:01 | Edited Transcript of MDCO earnings conference call or presentation 27-Feb-19 1:30pm GMT

2019-02-27 12:57:01 | Medicines Co MDCO Q4 2018 Earnings Conference Call Transcript

2019-02-27 07:00:00 | The Medicines Company Reports Fourth-Quarter and Full Year 2018 Business and Financial Results

2019-02-21 07:00:00 | The Medicines Company Announces Upcoming Investor Conference Presentations

2019-02-20 07:00:00 | The Medicines Company to Announce Fourth-Quarter and Full-Year 2018 Financial Results on February 27

2019-02-13 10:31:03 | Will Medicines Co. MDCO Report Negative Q4 Earnings? What You Should Know

2019-02-08 08:54:01 | Is the Options Market Predicting a Spike in Medicines Company MDCO Stock?

2019-02-08 08:06:28 | See what the IHS Markit Score report has to say about Medicines Co.

2019-02-08 07:50:39 | [$$] FT Health: Combating cancer; Brexit and EU medicine verification

2019-02-08 07:47:12 | Alnylam's ALNY Q4 Earnings and Revenues Beat Estimates

2019-02-01 06:47:01 | [$$] FT Health: Is Big Food ripe for the Big Tobacco treatment?

2019-01-30 08:10:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Leidos, Nomad Foods, Huron Consulting Group, Casella Waste, The Medicines, and Aurinia Pharmaceuticals — New Research Emphasizes Economic Growth

2019-01-29 08:02:40 | See what the IHS Markit Score report has to say about Medicines Co.

2019-01-28 01:11:50 | [$$] UK shows leadership on anti-microbial resistance

2019-01-22 14:38:42 | Need To Know: The Medicines Company NASDAQ:MDCO Insiders Have Been Buying Shares

2019-01-18 05:00:00 | Top Picks 2019- The Medicines Company MDCO

2019-01-15 08:06:21 | See what the IHS Markit Score report has to say about Medicines Co.

2019-01-09 08:07:05 | See what the IHS Markit Score report has to say about Medicines Co.

2019-01-07 07:30:00 | The Medicines Company Announces 5th Review of Un-blinded Data and Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase 3 Trials

2019-01-04 05:00:25 | [$$] British schools explore EU expansion after Brexit

2019-01-03 08:42:01 | Implied Volatility Surging for Medicines Company MDCO Stock Options

2018-12-24 09:29:02 | Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III

2018-12-23 09:42:53 | Insider Buys Of The Week: Chesapeake Energy, Medicines Company, NuStar Energy

2018-12-20 08:06:53 | See what the IHS Markit Score report has to say about Medicines Co.

2018-12-18 18:15:03 | The Medicines Co MDCO CEO Mark Timney Bought $499,652 of Shares

2018-12-13 22:52:48 | Is The Medicines Company MDCO A Good Stock To Buy?

2018-12-13 21:43:00 | The Medicines Company Prices $150 Million of Convertible Notes

2018-12-13 17:37:00 | Here's Why Shares of The Medicines Company Sank 14.5% Today

2018-12-12 16:30:00 | The Medicines Company Announces Intention to Offer $150 Million of Convertible Notes

2018-12-11 07:28:00 | The Medicines Co. names Mark Timney CEO effective immediately

2018-12-11 07:23:00 | The Medicines Company Appoints Mark Timney as Chief Executive Officer

2018-12-08 09:30:02 | Medicines Co. MDCO Down 11% Since Last Earnings Report: Can It Rebound?

2018-12-06 23:29:05 | [$$] Health sector warned of 6-month medicine shortages in no-deal

2018-12-04 08:06:55 | See what the IHS Markit Score report has to say about Medicines Co.

2018-12-03 23:00:46 | [$$] Government prepares to ration ferry space under no-deal Brexit

2018-12-03 23:00:28 | [$$] Flexibility on cancer drugs approval will foster innovation

2018-11-27 08:07:26 | See what the IHS Markit Score report has to say about Medicines Co.

2018-11-22 08:07:05 | See what the IHS Markit Score report has to say about Medicines Co.

2018-11-21 23:03:27 | [$$] The Brexit political declaration: the key points